Abstract
Pharmacovigilance is an area of drug development that is increasingly found in the regulatory spotlight. As a result, companies need to have confidence in the quality and the accuracy of the data being used in the benefit-risk assessments of their products. Roche Products and Novartis have both introduced quality management systems into their pharmacovigilance operations. This paper discusses why such functions are considered necessary and the activities they carry out.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
